Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise

Research output: Contribution to journalArticlepeer-review

Abstract

Capillary malformation-arteriovenous malformation (CM-AVM) syndrome is an autosomal dominant condition characterized by multifocal, noncontiguous pink patches on the skin that often have a surrounding pale halo. In some cases, an association with a fast flow, arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16-year-old woman with CM-AVM syndrome and significant cardiac compromise successfully treated with trametinib, a mitogen-activated protein kinase (MEK) inhibitor.

Original languageEnglish (US)
Pages (from-to)316-319
Number of pages4
JournalPediatric Dermatology
Volume39
Issue number2
DOIs
StatePublished - Mar 1 2022

Bibliographical note

Funding Information:
The authors thank Timothy Moss, MD PhD and Denise Adams, MD for their aid in the management decisions in this case.

Publisher Copyright:
© 2022 Wiley Periodicals LLC.

Keywords

  • MEK inhibitor
  • skin signs of systemic disease
  • therapy-systemic
  • trametinib
  • vascular malformation

PubMed: MeSH publication types

  • Case Reports
  • Journal Article

Fingerprint

Dive into the research topics of 'Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise'. Together they form a unique fingerprint.

Cite this